Publications by authors named "S Magina"
CheckAP: Prevalence of psoriatic arthritis (PsA) and performance evaluation of the EARP questionnaire in the population of Portuguese patients with psoriasis followed in a dermatology setting.
Ana Rita Henriques Fernando Pimentel-Santos João Teles de Sousa Leandro Silva Laura Gago Sofia Magina
ARP Rheumatol
January 2024
Background: The percentage of Portuguese psoriasis patients with psoriatic arthritis is unknown but musculoskeletal complaints related to PsA affect up to a third of patients. Dermatologists can identify early PsA as skin symptoms often precede joint symptoms in 80% of patients. Efficient and easy to perform screening tools are needed to help dermatologists effectively discriminate between Pso and PsA patients.
View Article and Find Full Text PDFArticle Synopsis
- - The study focused on Generalized Pustular Psoriasis (GPP), a rare and serious skin condition, examining its course, treatment approaches, and how often patients used healthcare services in Portugal from 2002 to 2023.
- - It assessed 59 adult patients, revealing that most had a history of another psoriasis type and faced significant health issues, with 64% requiring hospitalization and many experiencing severe symptoms such as fever and high white blood cell counts.
- - Despite treatment, 98% of patients had at least one flare-up, and only a small number showed improvement by the study's end, indicating a need for better understanding and new treatment options to alleviate the disease's impact.
Article Synopsis
- - Psoriasis is a chronic skin condition that impacts quality of life and requires ongoing treatment; this study focused on factors affecting adherence to topical treatment among 102 patients.
- - Researchers used self-reported measures, weighing medicine, and the Brief Symptoms Inventory to evaluate treatment adherence and associated psychosocial and clinical factors.
- - Findings indicated that education level, living alone, employment status, family history of psoriasis, and obsessive-compulsive symptoms had significant effects on adherence to treatment, highlighting the need for tailored instructions to improve compliance.
Article Synopsis
- This study assessed the effectiveness of tildrakizumab, a biologic drug, for treating moderate-to-severe psoriasis over 52 weeks in Portugal, revealing significant improvements in patients’ conditions.* ! -
- Out of 54 participants, mean PASI scores dropped drastically from 17.8 at the start to 1.3 by week 52, with over 85% achieving a PASI score of 5 or lower.* ! -
- The findings indicate that tildrakizumab is both effective and generally safe, with only a small percentage of patients experiencing infections and a high treatment continuation rate of 88.9% after 52 weeks.* !